UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration

Finger, RP; Schmitz-Valckenberg, S; Schmid, M; Rubin, GS; Dunbar, H; Tufail, A; Crabb, DP; ... MACUSTAR Consortium, .; + view all (2019) MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration. Ophthalmologica , 241 (2) pp. 61-72. 10.1159/000491402. Green open access

[thumbnail of Rubin VoR 491402.pdf]
Preview
Text
Rubin VoR 491402.pdf - Published Version

Download (346kB) | Preview
[thumbnail of Supplementary files] Archive (Supplementary files)
Finger_7016390.zip

Download (228kB)

Abstract

PURPOSE: Currently, no outcome measures are clinically validated and accepted as clinical endpoints by regulatory agencies for drug development in intermediate age-related macular degeneration (iAMD). The MACUSTAR Consortium, a public-private research group funded by the European Innovative Medicines Initiative intends to close this gap. PROCEDURES: Development of study protocol and statistical analysis plan including predictive modelling of multimodal endpoints based on a review of the literature and expert consensus. RESULTS: This observational study consists of a cross-sectional and a longitudinal part. Functional outcome measures assessed under low contrast and low luminance have the potential to detect progression of visual deficit within iAMD and to late AMD. Structural outcome measures will be multimodal and investigate topographical relationships with function. Current patient-reported outcome measures (PROMs) are not acceptable to regulators and may not capture the functional deficit specific to iAMD with needed precision, justifying development of novel PROMs for iAMD. The total sample size will be n = 750, consisting mainly of subjects with iAMD (n = 600). CONCLUSIONS: As clinical endpoints currently accepted by regulators cannot detect functional loss or patient-relevant impact in iAMD, we will clinically validate novel candidate endpoints for iAMD.

Type: Article
Title: MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration
Location: Switzerland
Open access status: An open access version is available from UCL Discovery
DOI: 10.1159/000491402
Publisher version: https://doi.org/10.1159/000491402
Language: English
Additional information: This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission.
Keywords: Clinical endpoint, Disease progression, Intermediate age-related macular degeneration, Patient-reported outcomes, Structure-function correlation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
URI: https://discovery.ucl.ac.uk/id/eprint/10055645
Downloads since deposit
85Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item